RxDoctor Payments Data

Fernando Raudales, MD

Nephrology · El Paso, TXNPI 1801880307

Payments from drug & device makers

$30,201in general payments, 2019–2025

Across 673 payments — averaging $44.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aurinia Pharma U.S., Inc.$14K
  • AstraZeneca$3K
  • Amgen$3K
  • Vifor Pharma, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$972
  • Bayer$844
  • plus $8K from 36 others

What the payments were for

  • Consulting fees$1000%
  • Speaking & faculty fees$11,00036%
  • Travel & lodging$1,7406%
  • Food & beverage$16,93256%
  • Education$4291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,201 in reported general payments places this provider in the 85th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$137,550
Medicare patients
278
Services billed
1,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide42$197,373
FarxigaDapagliflozin Propanediol219$168,979
OzempicSemaglutide102$122,483
JardianceEmpagliflozin147$114,206
XphozahTenapanor Hcl26$73,023
JanuviaSitagliptin Phosphate48$41,296
TrulicityDulaglutide28$36,874
VeltassaPatiromer Calcium Sorbitex23$33,923
EliquisApixaban46$27,326
RayaldeeCalcifediol19$23,125
AuryxiaFerric Citrate17$20,027
Sevelamer Carbonate57$18,520
TradjentaLinagliptin21$17,637
Envarsus XrTacrolimus12$14,490
KerendiaFinerenone16$13,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$285$197,37342 claims
AstraZenecaFarxiga$2,701$168,979219 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy, Jentadueto$275$147,414200 claims
Novo NordiskOzempic$172$122,483102 claims
MerckJanuvia$281$41,29648 claims
Lilly USA, LLCTrulicity$102$36,87428 claims
PfizerEliquis$88$27,32646 claims
OPKO Pharmaceuticals, LLCRayaldee$669$23,12519 claims
Akebia Therapeutics IncAuryxia$733$20,02717 claims
BayerKerendia$844$13,66216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,070 nephrology providers in Texas.

Other nephrology in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →